cilia and flagella associated protein 46Genealiases: C10orf123 · C10orf124 · C10orf92 · C10orf93 · TTC40 · bA288G11.4
Q-omics provides the consensus-scored CFAP46 profile across patient tissues and cancer cell-line models. CFAP46 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CFAP46 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, CFAP46 RNA expression shows 17,456 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BRCA, THCA, and KIRP as cancer lineages where CFAP46 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFAP46 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFAP46 survival associations across molecular data types. CFAP46 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFAP46 RNA expression–survival associations across cancer types. High CFAP46 expression shows unfavorable associations in ACC and LGG, but favorable associations in BRCA, KIRP, UVM and CESC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for CFAP46 RNA expression.
This table summarizes CFAP46 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CFAP46. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFAP46 shows lower tumor expression in THCA, KICH, KIRC, LUSC, LUAD and HNSC. The THCA box plot shows higher CFAP46 RNA expression in normal versus tumor tissue (log2 FC = −1.621, t-test p < 0.001).
This table shows molecular features associated with CFAP46 in patient tissues and cancer cell lines. In patient samples, CFAP46 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CFAP46 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
